COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth
Novartis Still Dominates Pipeline But Roche Catches Up
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
You may also be interested in...
New development programs fell sharply in the early part of the year as COVID-19 spread around the world, but activity picked up in the second half. Oncology trials rebounded strongly and infectious disease trials ballooned, but autoimmune and CNS studies took a hit.
AstraZeneca’s CEO Pascal Soriot confirmed the death of distinguished cancer researcher and head of its oncology R&D unit, José Baselga, on 21 March.
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.